8-K: CNBX Pharmaceuticals Appoints New Independent Auditor, Replacing Weinstein International CPA
Change of Auditor Announcement
CNBX Pharmaceuticals has replaced its independent auditor, Weinstein International CPA, with Elkana Amitai, CPA, effective March 18, 2024.
Summary
- CNBX Pharmaceuticals has changed its independent registered public accounting firm.
- Weinstein International CPA was replaced by Elkana Amitai, CPA, effective March 18, 2024.
- The change was not due to any disagreements with the former accounting firm.
- The decision was made by the Board of Directors on March 18, 2024.
- There were no disagreements with Weinstein International CPA on accounting principles, financial statement disclosure, or auditing scope during their tenure.
- There were no reportable events as defined in Item 304(a)(1)(v) of Regulation S-K during the period of engagement with Weinstein International CPA.
Sentiment
Score: 7
Explanation: The document indicates a routine change of auditors with no negative implications, suggesting a stable and well-managed company. The lack of disagreements is a positive sign.
Positives
- The transition to a new auditor was smooth and without any disagreements, indicating a healthy relationship with the previous auditor.
- The company has secured a new auditor in a timely manner.
Management Comments
- The Board made the decision to engage the New Accounting Firm acting under authority delegated to it and the Board of Directors approved the same on March 18th, 2024.
Industry Context
Changes in auditors are not uncommon, but it is important to note that this change was not due to any disagreements, which is a positive sign for the company's financial health and transparency.
Comparison to Industry Standards
- The process of changing auditors is a standard practice in the industry, and the fact that there were no disagreements is a positive sign.
- Many companies change auditors periodically for various reasons, including cost, expertise, or rotation policies.
- The smooth transition and confirmation from the previous auditor are in line with best practices for corporate governance.
Stakeholder Impact
- The change in auditor is unlikely to have a significant impact on stakeholders, as it was a routine change without any disagreements.
Key Dates
| Date | Description |
|---|---|
| 2022-08-31 | End of the fiscal year for 2022. |
| 2022-11-30 | End of the first quarter of fiscal year 2023. |
| 2023-02-28 | End of the second quarter of fiscal year 2023. |
| 2023-05-31 | End of the third quarter of fiscal year 2023. |
| 2023-08-31 | End of the fiscal year for 2023. |
| 2024-03-18 | Effective date of the change in independent auditor and Board approval date. |
| 2024-03-21 | Date of the letter from the former accounting firm. |
| 2024-03-22 | Date of the 8-K filing. |
Keywords
auditor, accounting firm, independent auditor, CNBX Pharmaceuticals, Weinstein International CPA, Elkana Amitai CPA, financial statements, SEC
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.